Announcements Trials
Browse Landscape

Status

No longer available 3

Sponsor Class

INDUSTRY 3

Study Type

Expanded_access 3

Sponsor

Cancer Type

Other hematologic neoplasm 3Myeloid 1Lymphoid 1

Conditions

Leukemia, Myeloid, Acute 3Mastocytosis, Systemic 1Leukemia, Mast-Cell 1Leukemia 1

Interventions

trametinib 4nilotinib 4elotuzumab 4dabrafenib 4Amifampridine 4regorafenib 3pembrolizumab 3midostaurin 3fludarabine phosphate 3fludarabine 3Nivolumab 3Lenalidomide 3Ipilimumab 3Everolimus 3Dexamethasone 3Cyclophosphamide 3Crizotinib 3Bortezomib 3Axitinib 3venetoclax 2veliparib 2tazemetostat 2talimogene laherparepvec 2navitoclax 2gallium 68 PSMA-11 2ceritinib 2carbon-11 acetate 2aldesleukin 2Whole-Body Irradiation 2Trabectedin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
No longer available × Expanded_access × midostaurin × Clear all
NCT05219266 2024-06-28

Managed Access Programs for PKC412, Midostaurin

Novartis

No longer available
LymphoidMyeloidOther hematologic neoplasm

Leukemia, Mast-Cell, Leukemia, Myeloid, Acute, Mastocytosis, Systemic

NCT02624570 2020-07-15

AMLFLT3

Novartis

No longer available
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT03114228 2019-10-15

An Expanded Treatment Protocol (ETP) of Midostaurin (PKC412) in Patients 18 Years of Age or Older With Newly-diagnosed FLT3-mutated Acute Myeloid Leukemia (AML)

Novartis

No longer available
Other hematologic neoplasm

Leukemia, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡